Mindbio Therapeutics Corp. (TSE:MBIO) has released an update.
MindBio Therapeutics Corp. has completed the final milestone of its Phase 2A microdosing depression clinical trial, demonstrating a significant reduction in depressive symptoms with its lead drug, MB22001. The company is advancing further with multiple Phase 2B trials, including a groundbreaking trial approved for take-home use of MB22001. As one of the few public companies progressing in psychedelic medicines, MindBio stands out on the Canadian Securities Exchange.
For further insights into TSE:MBIO stock, check out TipRanks’ Stock Analysis page.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
